Palisades Park, New Jersey Clinical Trials

A listing of Palisades Park, New Jersey clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 517 clinical trials
Study Title Past Referrals2  

Study Overview

Site 3 Widget
 (7.8 away)
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
Study in Subjects With Relapsed/Refractory Follicular Lymphoma

This is a multicenter, double-blind, active-controlled, randomized, 3-stage, biomarker enrichment design featuring early futility stopping and sample-size re-estimation with safety run-in designed to evaluate the efficacy and safety of tazemetostat in combination with R2 in subjects with R/R FL, who have completed at least 1 prior systemic chemotherapy, immunotherapy, or …

systemic therapy
experimental therapy
systemic chemotherapy
refractory follicular lymphoma
tositumomab
Hackensack University Medical John Theurer Cancer Center
 (3.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +7 other locations
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good …

systemic therapy
refractory follicular lymphoma
hodgkin's disease
alkylating agents
leukapheresis
Memorial Sloan Kettering Cancer Center
 (5.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +35 other locations
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during …

tiragolumab
atezolizumab
carboplatin
extensive stage small cell lung cancer
cancer
Mount Sinai - PRIME; Icahn School of Medicine at Mount Sinai
 (4.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +146 other locations
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

macitentan
hypertension
ventricular septal defects
left ventricular end-diastolic pressure
ventricular septal defect
Columbia University
 (2.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +210 other locations
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine Cyclophosphamide and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale [CIRS]/score of 6 and a normal creatinine clearance of 70 mL/min) …

17p deletion
absolute neutrophil count
obinutuzumab
bendamustine
TP53
Regional Cancer Care Associates
 (3.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +50 other locations
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the …

cancer
gonadotropin releasing hormone
solid tumour
androgen suppression
antiandrogen therapy
Research Site
 (8.3 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +106 other locations
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

The primary objective of this study is to demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y, and W following administration of 2 doses of MenACYW conjugate vaccine compared to 2 doses of MENVEO when given concomitantly with routine pediatric vaccines to infants and toddlers 6 …

Investigational Site Number 8400069
 (5.3 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +46 other locations
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes.

Mount Sinai Medical Center
 (4.6 away) Contact site
  • 0 views
  • 05 Oct, 2021
  • +301 other locations
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II) (INTRAGO-II)

INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radiotherapy (IORT) to standard radiochemotherapy.

Lenox Hill Hospital, Hofstra Northwell School of Medicine
 (5.3 away) Contact site
  • 0 views
  • 20 Jul, 2022
  • +16 other locations